hsa-mir-362: Hsa-mir-362 is a microRNA that has been found to inhibit the proliferation and migration of vascular smooth muscle cells in atherosclerosis [PMC8782054]. In subjects with obesity, it has been observed that PCSK9 may impact the release of extracellular vesicles (EVs) derived from atherosclerotic components, including platelets, endothelium, monocytes/macrophages, and neutrophils. These EVs also contain miRNAs associated with atherosclerosis, such as hsa-mir-362 [PMC8782054]. In patients with renal cell carcinoma (RCC), the serum levels of hsa-miR-193a-3p, hsa-mir-362, and hsa-miR-572 were significantly increased [PMC6176358]. Hsa-mir-362 is one of the miRNAs that have been identified as potential biomarkers in various diseases. It has been found to be highly correlated with tsRNAs and is associated with prognostic outcomes [PMC8843861]. Hsa-mir-362 has also been linked to fetal teratogenesis and mental retardation in mice, suggesting its relevance in neurogenerative diseases [PMC4244954]. It is clustered with other miRNAs within 10 kb on the genome [PMC5698490]. Additionally, hsa-mir-362 has been identified as one of the miRNAs that can predict target genes in multiple databases [PMC4735861]. Overall, hsa-mir-362 plays a role in various biological processes and may have potential implications as a biomarker for different diseases.